Nutriband Inc. Reports Q2 2026 Revenue of $0.6M, Highlighting 50% YoY Growth in Contract Manufacturing Sales

Reuters09-12

<a href="https://laohu8.com/S/NTRB">Nutriband Inc.</a> Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2026 Revenue of $0.6M, Highlighting 50% YoY Growth in Contract Manufacturing Sales

Nutriband Inc. reported its Q2 2026 financial results, showing a revenue increase to $0.6 million, driven by a 50% year-over-year rise in contract manufacturing revenue, largely due to increased kinesiology tape production through Pocono Pharma. The company concluded the quarter with $6.9 million in cash. A significant development includes the upcoming FDA Type C meeting scheduled for September 18, 2025, to discuss the Phase 1 clinical trial for the AVERSA Fentanyl patch, which integrates an opioid with Nutriband's proprietary abuse-deterrent technology. The company intends to extend the AVERSA platform to Buprenorphine, a key treatment for opioid dependence. Analysts have maintained an Outperform rating for Nutriband Inc., with a target price of $15, citing the company's strategic focus and growth in contract revenues as supportive of its clinical development efforts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief on September 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2567990385?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 23:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567990385","market":"nz","top_or_hot":-1,"title":"Nutriband Inc. Reports Q2 2026 Revenue of $0.6M, Highlighting 50% YoY Growth in Contract Manufacturing Sales","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NTRB\">Nutriband Inc.</a> Reports <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026 Revenue of $0.6M, Highlighting 50% YoY Growth in Contract Manufacturing Sales\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nutriband Inc. reported its Q2 2026 financial results, showing a revenue increase to $0.6 million, driven by a 50% year-over-year rise in contract manufacturing revenue, largely due to increased kinesiology tape production through Pocono Pharma. The company concluded the quarter with $6.9 million in cash. A significant development includes the upcoming FDA Type C meeting scheduled for September 18, 2025, to discuss the Phase 1 clinical trial for the AVERSA Fentanyl patch, which integrates an opioid with Nutriband's proprietary abuse-deterrent technology. The company intends to extend the AVERSA platform to Buprenorphine, a key treatment for opioid dependence. Analysts have maintained an Outperform rating for Nutriband Inc., with a target price of $15, citing the company's strategic focus and growth in contract revenues as supportive of its clinical development efforts.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief on September 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nutriband Inc. Reports Q2 2026 Revenue of $0.6M, Highlighting 50% YoY Growth in Contract Manufacturing Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNutriband Inc. Reports Q2 2026 Revenue of $0.6M, Highlighting 50% YoY Growth in Contract Manufacturing Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-12 23:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NTRB\">Nutriband Inc.</a> Reports <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026 Revenue of $0.6M, Highlighting 50% YoY Growth in Contract Manufacturing Sales\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nutriband Inc. reported its Q2 2026 financial results, showing a revenue increase to $0.6 million, driven by a 50% year-over-year rise in contract manufacturing revenue, largely due to increased kinesiology tape production through Pocono Pharma. The company concluded the quarter with $6.9 million in cash. A significant development includes the upcoming FDA Type C meeting scheduled for September 18, 2025, to discuss the Phase 1 clinical trial for the AVERSA Fentanyl patch, which integrates an opioid with Nutriband's proprietary abuse-deterrent technology. The company intends to extend the AVERSA platform to Buprenorphine, a key treatment for opioid dependence. Analysts have maintained an Outperform rating for Nutriband Inc., with a target price of $15, citing the company's strategic focus and growth in contract revenues as supportive of its clinical development efforts.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief on September 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTRB","symbol_name":"Nutriband Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDL2rhr8T:1","article_id":"2567990385","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567990385","pubTimestamp":1757692222,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nutriband Inc. reported its Q2 2026 financial results, showing a revenue increase to $0.6 million, driven by a 50% year-over-year rise in contract manufacturing revenue, largely due to increased kinesiology tape production through Pocono Pharma. The company concluded the quarter with $6.9 million in cash. A significant development includes the upcoming FDA Type C meeting scheduled for September 18, 2025, to discuss the Phase 1 clinical trial for the AVERSA Fentanyl patch, which integrates an opioid with Nutriband's proprietary abuse-deterrent technology. The company intends to extend the AVERSA platform to Buprenorphine, a key treatment for opioid dependence. Analysts have maintained an Outperform rating for Nutriband Inc., with a target price of $15, citing the company's strategic focus and growth in contract revenues as supportive of its clinical development efforts.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT st","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NTRB":"Nutriband Inc."},"translate_title":"Nutriband Inc.报告2026年第二季度收入为60万美元，合同制造销售额同比增长50%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRB":0.9},"content_text":"Nutriband Inc. Reports Q2 2026 Revenue of $0.6M, Highlighting 50% YoY Growth in Contract Manufacturing Sales\n    \n\n        Nutriband Inc. reported its Q2 2026 financial results, showing a revenue increase to $0.6 million, driven by a 50% year-over-year rise in contract manufacturing revenue, largely due to increased kinesiology tape production through Pocono Pharma. The company concluded the quarter with $6.9 million in cash. A significant development includes the upcoming FDA Type C meeting scheduled for September 18, 2025, to discuss the Phase 1 clinical trial for the AVERSA Fentanyl patch, which integrates an opioid with Nutriband's proprietary abuse-deterrent technology. The company intends to extend the AVERSA platform to Buprenorphine, a key treatment for opioid dependence. Analysts have maintained an Outperform rating for Nutriband Inc., with a target price of $15, citing the company's strategic focus and growth in contract revenues as supportive of its clinical development efforts.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief on September 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2567990385","isCrawlerRequest":true}